Topical Fluoxetine as a Potential Nonantibiotic Adjunctive Therapy for Infected Wounds

J Invest Dermatol. 2021 Jun;141(6):1608-1612.e3. doi: 10.1016/j.jid.2020.11.016. Epub 2020 Dec 15.

Authors

Daniel J Yoon¹, Chuong Nguyen¹, Michelle D Bagood¹, Daniel R Fregoso¹, Hsin-Ya Yang¹, Andrea I Medina Lopez¹, Robert W Crawford², Jennifer Tran², R Rivkah Isseroff³

Affiliations

¹ Department of Dermatology, University of California, Davis, Sacramento, California, USA.
² Department of Biological Sciences, California State University, Sacramento, Sacramento, California, USA.
³ Department of Dermatology, University of California, Davis, Sacramento, California, USA. Electronic address: [email protected].

PMID: 33338500
DOI: 10.1016/j.jid.2020.11.016

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Biofilms / drug effects
Chronic Disease / drug therapy
Drug Therapy, Combination / methods
Fluoxetine / pharmacology*
Fluoxetine / therapeutic use
Gene Expression Regulation, Bacterial / drug effects
Humans
Re-Epithelialization / drug effects
Selective Serotonin Reuptake Inhibitors / pharmacology*
Selective Serotonin Reuptake Inhibitors / therapeutic use
Skin / injuries
Skin / microbiology
Staphylococcus aureus / drug effects
Staphylococcus aureus / isolation & purification
Virulence Factors / genetics
Wound Infection / drug therapy*
Wound Infection / microbiology

Substances

Serotonin Uptake Inhibitors
Virulence Factors
Fluoxetine